Author(s): Parul Bali, Debomoy K. Lahiri, Avijit Banik, Bimla Nehru and Akshay Anand
Alzheimer’s disease (AD) is one of the most common causes of dementia. Despite several decades of research in AD, there is no standard disease- modifying therapy available and currentlyapproved drugs provide only symptomatic relief. Stem cells hold immense potential to regenerate damaged tissues and are currently tested in some brain-related disorders, such as AD, amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). We review stem cell transplantation studies using preclinical and clinical tools. We describe different sources of stem cells used in various animal models and explaining the putative molecular mechanisms that can rescue neurodegenerative disorders. The clinical studies suggest safety, efficacy and translational potential of stem cell therapy. The therapeutic outcome of stem cell transplantation has been promising in many studies, but no unifying hypothesis can convincingly explain the underlying mechanism. Some studies have reported paracrine effects exerted by these stem cells via the release of neurotrophic factors, while other studies describe the immunomodulatory effects exerted by the transplanted cells. There are also reports which indicate that stem cell transplantation might result in endogenous cell proliferation or replacement of diseased cells. In animal models of AD, stem cell transplantation is also believed to increase expression of synaptic proteins.
Read more here: http://benthamscience.com/journals/current-alzheimer-research/volume/14/issue/2/page/208/
Current Molecular Medicine is an interdisciplinary journal focused on providing the readership with current and comprehensive reviews, original research articles, short communications/letters and drug clinical trial studies on fundamental molecular mechanisms of disease pathogenesis, the development of molecular-diagnosis and/or novel approaches to rational treatment. The reviews should be of significant interest to basic researchers and clinical investigators in molecular medicine. Periodically the journal invites guest editors to devote an issue on a basic research area that shows promise to advance our understanding of the molecular mechanism(s) of a disease or has potential for clinical applications.
Articles from the journal Current Molecular Medicine 16, Issue 9:
Article by Disease on “Pediatrics and Neonatology”
Background: Malaria is an important cause of death and illness in children worldwide. Most cases of neonatal malaria are misdiagnosed because of lack of specific symptoms and general lack of awareness. Nothing much is known in literature about the hematological changes during malaria infection and outcome of disease in neonates. Neonatal malaria is an underdiagnosed entity. So this hospital based observational study aims to assess diagnostic features of neonatal malaria.
Methods: From August 2004 to August 2013, information of all slide positive for malaria cases aged 0 to 28 days admitted to our pediatric hospital was collected and analysed.Results: 28 slide positive cases of neonatal malaria were studied, four out of them were congenital malaria. Fever (93%) was the most common symptom followed by pallor (72%) and diarrhoea (50%). We also found respiratory distress in four (14%) cases. Apart from anemia and atypical lymphocytosis, We also found thrombocytopenia and low hematocrit, MCV and RBC count. Two cases with bleeding manifestations expired during course of treatment.Discussion: Malaria in the first few months of life can simulate transplacentally or postnatally acquired infection such as TORCH, syphilis, neonatal hepatitis and septicemia all having an important symptom complex of fever jaundice, hepatosplenomegaly and anemia. Although in our cases clinical presentation has been similar to septicemia but culture of blood, CSF and urine were sterile. The dilemma of distinguishing neonatal malaria alone versus neonatal sepsis or both existing does not seem to be easily resolved by the use of clinical features alone. The laboratory diagnosis of parasitemia in neonates require special attention in Giemsa staining as well as the technical skill involved in malaria microscopy because parasite densities are low. So high degree of suspicion is needed to diagnose malaria in newborns presenting with fever and anemia.
Read more: http://benthamscience.com/journals/current-pediatric-reviews/volume/12/issue/4/page/286/
Recent Patents on Anti-Infective Drug Discovery publishes review and research articles, drug clinical trial studies and guest edited thematic issues on recent patents in the field of anti-infective drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to anti-infective drug discovery.
Articles from the journal Recent Patents on Anti-Infective Drug Discovery 11, Issue 2:
For details on the articles, please visit this link :: http://bit.ly/2jOO7Ls
Cancer treatment is still one of the most intractable challenge for medicine. There are several approaches to fight cancer, which include: surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy and hormone therapy. From all these treatment methods, chemotherapy seems to be the most widely used. Therefore, it is understandable that scientists are trying to discover new molecules which may be applied as effective chemotherapeutics.
The researchers from Jan Dugosz University in Czstochowa and Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences reviewed the most significant achievements in the area of cancer treatment, published in 2014/2015. This review describes newly discovered anticancer molecules interacting with DNA or affecting cancer cell cycles. New cancer treatment strategies, which increase efficiency of chemotherapy or radiotherapy and new chemotherapeutic delivery systems have also been mentioned in the review. Multiplicity of the described compounds proves that cancer battle is still in progress. We constantly learn something new about cancer cells and hopefully we are getting closer to find effective cancer treatment. We know that molecules can interact with cancer DNA by inhibiting its synthesis, transcription or duplication.
Chemotherapeutics are also able to affect tumor cell cycle by suppressing itsproliferation and angiogenesis, and also promoting its apoptosis.
However, developing effective cancer treatment is, still, a demanding task because the number of cancer cell-types known to researchers constantly increases. In spite of all these odds, we hope that along with the development of science, people will win the race with still incurable cancers.
Reference: Turek, M.; (2016). New Hopes in Cancer Battle – A Review of New Molecules and Treatment Strategies Med. Chem., DOI: 10.2174/1573406412666160502153700
For more information about the article, please visit: http://benthamscience.com/journals/medicinal-chemistry/article/141662/
Leprosy, also known as Hansen’s disease (HD), is a long-term infection by the bacteria Mycobacterium leprae. Symptoms of leprosy include granulomas of the nerves, respiratory tract, skin, and eyes, which result in lack of ability to feel pain.
Bentham Science publishes research papers that present new studies to help eradicate Leprosy. Find the latest studies in the following journals:
Immunology‚ Endocrine & Metabolic Agents in Medicinal Chemistry, Infectious Disorders – Drug Targets, Current Immunology Reviews
SMI is proud to announce their 17th Annual Pain Therapeutics 2017 event in London, UK on the 22nd -23rd May 2017!
Created with an expert scientific advisory board, SMi’s 17th annual Pain Therapeutics conference will hone in on the latest innovations and novel approaches to pain therapy and analgesic drugs as well as look at the practicalities of using animal models and translational biomarkers in pain research. Aimed at an audience of scientific leaders and senior specialists in neuroscience, CNS, clinical operations and pharmacology, Pain Therapeutics 2017 will keep attendees at the forefront of medical breakthroughs to adapt to the growing need towards minimising opioid dependency and new drug discovery.
Presentations from a selection of hand-picked pharmaceutical companies currently developing novel treatments in pain, will provide delegates with an understanding on key topics such as product formulation; opioid addiction; translational pain research; and breakthroughs in drug discovery. Interactive workshops and exclusive new findings from phase II clinical trials will be just some of the highlights at the 17th annual show when it returns to London this spring.
Visit the website for further details at http://www.pain-therapeutics.co.uk/bentham or contact the team on +44 (0)20 7827 6000 / email: firstname.lastname@example.org
Journal: CNS & Neurological Disorders – Drug Targets
EBook: Frontiers in Clinical Drug Research- Central Nervous System